Company Overview - Carmell Corporation is a bioaesthetics company focused on skin and hair health, utilizing the Carmell Secretome™ which consists of growth factors and proteins from allogeneic human platelets [4] - The company has developed a microemulsion formulation that avoids harmful excipients commonly used in cosmetic products, ensuring non-comedogenic properties [4] Private Placement Details - Carmell announced a private placement for the issuance and sale of 8,065,210 shares of common stock and an equal number of five-year warrants, both priced at $0.23 per share, resulting in gross proceeds of $1.85 million [1][3] - The private placement was priced at a slight premium to the closing price of CTCX on December 23, 2024, and the warrants, if exercised, could generate an additional $1.85 million [1][3] - Following the private placement, the company will have approximately 29 million shares of common stock outstanding [3] Investment and Future Plans - The investment aims to support the continued commercial development of Carmell's bioaesthetics product pipeline, as stated by the Chairman of Carmell [8] - Brookline Capital Markets served as the exclusive placement agent for the private placement [8]
Carmell Announces PIPE Investment From Existing and New Investors To Support Commercial Build-out